Targeting protein kinase C

A novel paradigm for heart failure therapy

Research output: Contribution to journalReview article

Abstract

Heart failure continues to be a disease associated with significant morbidity and mortality in both children and adults. Guidelines exist for the recommended management of heart failure in both populations. Many of these therapies are targeted at the neurohormonal response that occurs in heart failure. Although recent additions have been made to the guidelines for the use of novel oral therapies in heart failure, the impact of these therapies in real-world practice remains to be seen. There are additional targets in heart failure that have been unexplored in clinical studies. One such target is the protein kinase C family of proteins which have deleterious effects in the setting of heart failure. Herein, we will explain the rationale for targeting these proteins and discuss an ongoing clinical trial to assess for safety and efficacy of a drug that directly inhibits some of the isozymes of the protein kinase C family, protein kinase C α and β.

Original languageEnglish (US)
Pages (from-to)53-56
Number of pages4
JournalProgress in Pediatric Cardiology
Volume49
DOIs
StatePublished - Jun 1 2018
Externally publishedYes

Fingerprint

Protein Kinase C
Heart Failure
Therapeutics
Guidelines
Protein Transport
Isoenzymes
Clinical Trials
Morbidity
Safety
Mortality
Pharmaceutical Preparations
Population
Proteins

All Science Journal Classification (ASJC) codes

  • Pediatrics, Perinatology, and Child Health
  • Cardiology and Cardiovascular Medicine

Cite this

Targeting protein kinase C : A novel paradigm for heart failure therapy. / Jefferies, John.

In: Progress in Pediatric Cardiology, Vol. 49, 01.06.2018, p. 53-56.

Research output: Contribution to journalReview article

@article{45e4cd1f4eb646a4a4236606fcc490df,
title = "Targeting protein kinase C: A novel paradigm for heart failure therapy",
abstract = "Heart failure continues to be a disease associated with significant morbidity and mortality in both children and adults. Guidelines exist for the recommended management of heart failure in both populations. Many of these therapies are targeted at the neurohormonal response that occurs in heart failure. Although recent additions have been made to the guidelines for the use of novel oral therapies in heart failure, the impact of these therapies in real-world practice remains to be seen. There are additional targets in heart failure that have been unexplored in clinical studies. One such target is the protein kinase C family of proteins which have deleterious effects in the setting of heart failure. Herein, we will explain the rationale for targeting these proteins and discuss an ongoing clinical trial to assess for safety and efficacy of a drug that directly inhibits some of the isozymes of the protein kinase C family, protein kinase C α and β.",
author = "John Jefferies",
year = "2018",
month = "6",
day = "1",
doi = "10.1016/j.ppedcard.2018.05.006",
language = "English (US)",
volume = "49",
pages = "53--56",
journal = "Progress in Pediatric Cardiology",
issn = "1058-9813",
publisher = "Elsevier Ireland Ltd",

}

TY - JOUR

T1 - Targeting protein kinase C

T2 - A novel paradigm for heart failure therapy

AU - Jefferies, John

PY - 2018/6/1

Y1 - 2018/6/1

N2 - Heart failure continues to be a disease associated with significant morbidity and mortality in both children and adults. Guidelines exist for the recommended management of heart failure in both populations. Many of these therapies are targeted at the neurohormonal response that occurs in heart failure. Although recent additions have been made to the guidelines for the use of novel oral therapies in heart failure, the impact of these therapies in real-world practice remains to be seen. There are additional targets in heart failure that have been unexplored in clinical studies. One such target is the protein kinase C family of proteins which have deleterious effects in the setting of heart failure. Herein, we will explain the rationale for targeting these proteins and discuss an ongoing clinical trial to assess for safety and efficacy of a drug that directly inhibits some of the isozymes of the protein kinase C family, protein kinase C α and β.

AB - Heart failure continues to be a disease associated with significant morbidity and mortality in both children and adults. Guidelines exist for the recommended management of heart failure in both populations. Many of these therapies are targeted at the neurohormonal response that occurs in heart failure. Although recent additions have been made to the guidelines for the use of novel oral therapies in heart failure, the impact of these therapies in real-world practice remains to be seen. There are additional targets in heart failure that have been unexplored in clinical studies. One such target is the protein kinase C family of proteins which have deleterious effects in the setting of heart failure. Herein, we will explain the rationale for targeting these proteins and discuss an ongoing clinical trial to assess for safety and efficacy of a drug that directly inhibits some of the isozymes of the protein kinase C family, protein kinase C α and β.

UR - http://www.scopus.com/inward/record.url?scp=85047264637&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85047264637&partnerID=8YFLogxK

U2 - 10.1016/j.ppedcard.2018.05.006

DO - 10.1016/j.ppedcard.2018.05.006

M3 - Review article

VL - 49

SP - 53

EP - 56

JO - Progress in Pediatric Cardiology

JF - Progress in Pediatric Cardiology

SN - 1058-9813

ER -